What question did this study set out to answer?

This review assesses the barriers that prevent cinnamaldehyde derivatives from being used in clinical settings despite their promising preclinical findings.

May 26, 2026

Recent Advancements and Clinical Translation of Cinnamaldehyde Derivatives in Therapeutics

Key Points

This review assesses the barriers that prevent cinnamaldehyde derivatives from being used in clinical settings despite their promising preclinical findings.
Systematic evaluation of pharmacokinetic profiles and toxicity assessments of cinnamaldehyde derivatives.
Analysis of factors like aqueous solubility, metabolism, and reactive properties affecting clinical translation.
Cinnamaldehyde derivatives show efficacy in oncological, antiviral, and anti-inflammatory models.
Obstacles include poor aqueous solubility (≈1 mg/mL), rapid metabolism, and insufficient toxicity data.

Abstract

OBJECTIVE: This review systematically evaluates why CA derivatives have failed to transition from bench to bedside despite superior preclinical performance. SIGNIFICANCE: efficacy is negated by poor aqueous solubility (≈1 mg/mL), rapid first-pass metabolism, and a short plasma half-life (≈1.7 h). Also, the reactive α,β-unsaturated aldehyde moiety often triggers Pan-Assay Interference (PAINS) behavior. KEY FINDINGS: efficacy in oncological, antiviral, and anti-inflammatory models, progress is halted by a lack of human pharmacokinetic profiling and "safety bridging" toxicology. CONCLUSION: disconnection" through chemoproteomic target validation and IND-enabling PK studies is the essential next step for advancing this reactive scaffold into clinical trials.

Bookmark

Cite This Study

Shakir et al. (Sun,) studied this question.

synapsesocial.com/papers/6a153bdfb5d9c58d83e8d4c7 https://doi.org/https://doi.org/10.1080/03639045.2026.2678494

Bookmark